Sarah Lawrence College

DigitalCommons@SarahLawrence
Human Genetics Theses

The Joan H. Marks Graduate Program in
Human Genetics

5-2015

Diagnostic Dilemma: Mild and Moderate Forms of Osteogenesis
Imperfecta
LEYLA TABANFAR
Sarah Lawrence College

Follow this and additional works at: https://digitalcommons.slc.edu/genetics_etd

Recommended Citation
TABANFAR, LEYLA, "Diagnostic Dilemma: Mild and Moderate Forms of Osteogenesis Imperfecta" (2015).
Human Genetics Theses. 12.
https://digitalcommons.slc.edu/genetics_etd/12

This Thesis - Open Access is brought to you for free and open access by the The Joan H. Marks Graduate Program
in Human Genetics at DigitalCommons@SarahLawrence. It has been accepted for inclusion in Human Genetics
Theses by an authorized administrator of DigitalCommons@SarahLawrence. For more information, please contact
alester@sarahlawrence.edu.

Capstone Manuscript

DIAGNOSTIC DILEMMA:
MILD AND MODERATE FORMS OF OSTEOGENESIS IMPERFECTA

LEYLA TABANFAR

Joan H. Marks Graduate Program in Human Genetics
Sarah Lawrence College
Submitted in partial completion of the Master of Science Degree at Sarah Lawrence
College
May 2015

ABSTRACT - Osteogenesis imperfect (OI) is a group of genotypically and phenotypically
diverse disorders of connective tissue characterized by bone fragility. The classic typing

of OI includes: type I (mildest), type II (perinatally lethal), type III (most severe nonlethal) and type IV (moderate). Diagnosis and accurate typing of mild and moderate

types of OI are challenging due to the heterogeneity of OI and the lack of diagnostic

criteria. We did a retrospective review of 84 patient charts with a diagnosis of mild and
moderate forms of OI. We report on their diagnostic experience with the goal of

evaluating the role of genotyping in establishing and confirming a diagnosis of mild or

moderate OI. Our analysis supports the fact that no set of clinical data is diagnostic in
these cases and genetic testing has valuable utility. We further constructed a genotypephenotype map of our patient population, which can serve as an expandable tool for

clinicians and families in the ongoing management of patients with mild and moderate
types of OI.

INTRODUCTION
Classification of OI – Osteogenesis Imperfecta (OI) is a heterogenous group of skeletal

dysplasias characterized by bone fragility and therefore susceptibility to fractures. The

spectrum of severity of OI ranges from perinatally lethal to nearly asymptomatic, with
individuals who only have a mild propensity to fractures. The most widely accepted

classification of OI, which has remained the basis of the present day nosology, came in

1979 by Sillence et al. based on clinical characteristics and radiographic features. Type I
OI is the most common and mildest presentation with decreasing frequency of fractures

after puberty. Type II is perinatally lethal with multiple congenital fractures,

micromelia and severe lung disease. Types III is the most severe non-lethal form

presenting with multiple (congenital) fractures and severe and progressive bone

deformities. Type IV is an intermediate group that encompasses presentations that
cannot otherwise be categorized into the other types.

In 2004, Glorieux and Rauch expanded the original Sillence classification by adding
types V–VII. As more genetic causes of OI were discovered, nomenclature revisions

have been made to include up to OI type XIV (Forlino et al., 2011). Currently, there are a
total of 17 genetic causes of OI described in the literature (Van Dijk and Sillence, 2014).

There is ongoing debate about classification and subdivisions into different types since
many new types of OI are not distinguishable clinically from the classically defined
Sillence types (van Dijk et al., 2010).

Genotype-Phenotype Relationship – OI is as diverse genotypically as it is
phenotypically. The genetic defect is either directly or indirectly related to the

biosynthesis of type 1 collagen, the main structural constituent of bones, tendons and
ligaments. The individuals that fall into the four classic Sillence categories comprise
over 90% of cases of OI and are heterozygous for dominant mutations of either the
Col1α1 or Col1α2 genes, which respectively encode the proα1(I) and proα2(I) chains of

type I procollagen (Engel and Prockop, 1991; Byers et al. 1991). Type I collagen is a

heterotrimer composed of two alpha 1 and one alpha 2 chains. The peptide sequence of
the chains contains uninterrupted repeats of Gly-X-Y. The glycine residue in every third

position of the chains is necessary for the correct formation of the triple helix (Ben
Amor et al, 2011).

The mildest phenotype (type I OI) is usually a consequence of a quantitative defect of

collagen type I (Byers 2000 and 2002). In these cases only about half the normal
amount of type I collagen is produced because a nonsense, frameshift or splice site
mutation has introduced premature termination of Col1α1, resulting in degradation of

non-sense mRNA. Rarely, substitutions for glycine by small amino acids (cysteine,
alanine and serine) near the N-terminus of either the alpha 1 or alpha 2 chains result in
type I OI as well.

On the other hand, more severe phenotypes are typically a result of mutations that
disrupt the structure of either chain of type I collagen. Most commonly, mutations that

replace the glycine residues of the triple helix are responsible because they delay helix

formation and prolong duration of post-transcriptional modifications, which ultimately

produce structurally defective collagen. The resulting phenotypes vary in severity,
causing the dominantly inherited OI types II-IV (van Dijk et al., 2012). Less commonly

these phenotypes can result from mutations in the C-terminus, insertion/deletion or
missense mutations that cause structural abnormalities in collagen type I chains as well.

These genotype-phenotype correlations are by no means absolute. Establishing
correlations are further complicated by the fact that most OI mutations are unique. To

date, there have been more than 2000 different mutations of type I collagen reported in
a public access database (http://www.le.ac.uk/ge/collagen/) (Dalgleish, 1998).

The pathogenic pathways responsible for the remaining cohort of OI patients who do

not have a dominantly inherited collagen mutation, have been attributed to null
mutations of genes that interact with collagen post-translationally (Marini and Blissett,

2013). Type V OI is an exception overall in that it has distinct clinical features and is a

result of one specific dominantly inherited mutation in IFITM5. The other non-Sillence
types of OI range in severity from moderate to lethal and are inherited in an
autosomally recessive manner. So far, genes have been identified that are involved in

collagen folding (CRTAP, LEPRE1 and PPIB), chaperoning (FKBP10 and SERPINH1),

modification and cross-linking (PLOD2), bone mineralization (SERPINF1) and bone cell
differentiation (SP7, TMEM38B and WNT1) (Marini and Blissett, 2013).

Diagnostic Dilemma – There are no specific criteria set for the diagnosis of OI.

Clinically, the hallmark feature is the presence of fractures in the absence of trauma.
Blue/grey sclera, dentinogenesis imperfecta (DI), hearing loss and other bone

deformities vary in presentation. Historically, biochemical collagen screening has been
the gold standard of confirming an OI diagnosis. Collagen screening involves taking a

skin biopsy, followed by culture of the dermal fibroblasts, and biochemical assay of the
excreted collagen showing reduced or abnormal procollagen (Steiner et al., 1996;

Cabral et al., 2006). This is an invasive, time-consuming procedure, often taking up to
two months, and typically providing definitive identification of a collagen defect in up to

90% of cases (Wenstrup et al., 1990). With the discovery of causative mutations in

Col1α1 and Col1α2, confirmatory molecular testing for mutations in these genes can be
performed on a blood or tissue sample providing results in 4-8 weeks. With accurate

clinical diagnosis, more than 95% of individuals with OI have a mutation detected with
genomic sequencing (Sykes et al., 1990; Körkkö et al., 1998).

The heterogeneity of OI can be a confounding factor in its diagnosis. When a severe

phenotype is present, any qualified physician can diagnose the disease. Milder
phenotypes are more difficult to diagnose. There are other conditions that have

significant clinical overlap with OI including Ehlers Danlos Syndrome (EDS)

kyphoscoliotic type (type VIA), EDS arthrochalasia type (types VIIA and VIIB) and EDS

dermatosparaxis type (type VIIC) to name some (Steiner et al., 2013). The differential
diagnosis also includes premature aging syndromes in which fractures may be the first

manifestation and precede other clinical features (Van Dijk and Sillence, 2014).
Furthermore, non-accidental injury as a result of child abuse can present similar to OI
and importantly needs to be distinguished, though the two can coexist.

The diagnostic dilemma of OI is two-fold. In the mildest form or type I, it is not always
obvious whether OI exists or fracturing is due to another bone disease, (child) abuse or

an unknown cause. In the moderate form or type IV, the true severity of the condition
and whether the patient has been typed accurately can be subjective and based on
presenting clinical features at any given time. For example, if an unrelated 5 year old

and 50 year old both have had 5 fractures and do not exhibit other features, the

younger patient’s condition is likely to be classified as more severe (type IV) while the

older patient is likely to be classified as more mild (type I) even though they may have

the same genotype and similar phenotypes. Therefore, genetic testing has valuable

utility in establishing and confirming a diagnosis of OI in a quick, non-invasive and

accurate fashion. This in turn informs medical management, administration of

appropriate molecular therapies and evaluation of responses, likely prognosis and

recurrence risks. The goal of the present work has been to report on the diagnostic
criteria of patients with mild and moderate OI based on clinical and laboratory features,

at the Skeletal Dysplasias Clinic at the Hospital for Special Surgery. We further used this

information to catalogue genotype-phenotype correlations in our patient population
and compare our findings to the published literature.
MATERIALS & METHODS
We obtained approval for this research from the Institutional Review Board of the

Hospital for Special Surgery and conducted a retrospective chart review of 84 patients
who were diagnosed with mild and moderate forms of OI at the Kathryn O. and Alan C.

Greenberg Center for Skeletal Dysplasias at Hospital for Special Surgery. the Skeletal
Dysplasias Clinic. We excluded patients diagnosed with more severe forms of OI (types
II and III) or other metabolic bone or connective tissue disorders where fractures are a

main clinical finding.

In addition to the demographics, we collected all pertinent clinical information and

evaluations leading to the diagnosis of mild or moderate OI in an index case. We

collected data on fracture history, items identified in the physical exam and medical

history including evaluation of auditory, ophthalmologic, cardiopulmonary, and skeletal

systems and any treatment regimens and surgical procedures. In addition we reviewed
radiographic findings (including X-rays, DXA scans, CAT scans, MRI, and ultrasounds),

family history, and laboratory studies (biochemical and genetic testing, and other

serum and urinalysis). We hypothesized that definitive determination of a diagnosis of

mild or moderate OI is by direct genomic sequencing.

We de-identified our cohort for the analytic portion of this work and examined what

correlation, if any, existed between clinical findings, laboratory test results, family
history, and imaging results for individuals diagnosed with mild and moderate OI. In

this work, we report on our findings on the nine most commonly expressed features of

OI: fracture frequency, presence of blue/grey sclera, dentinogeneis imperfecta, hearing
loss, short stature, scoliosis, bone density loss, bone deformity and ligament laxity. Our

84 patients were grouped as (likely) having type I, type IV, or some other non-classic

Sillence type OI. For each of the nine features, the proportions of patients in each group

who exhibited the feature were calculated. To shed light on what role genotyping
played in the clinical diagnosis, we subdivided each group into those with genotype

information and those without. We then compared the percentage of genotyped
patients versus un-genotyped patients, exhibiting each of the nine cardinal features.

33 of the 84 patients had genotype information available and we used 30 of these

individuals who had a mutation in either Col1α1 or Col1α2 to further examine their

genotype-phenotype correlations. We catalogued the mutations of these patients, using

the OI Variant Database when possible and mapped the mutations on the
corresponding genes.
RESULTS

Figure 1A illustrates the number of patients in each category. Generally, there were

more type I patients than type IV patients and within each group, most patients had not

been genotyped. Figure 2 shows the fracture frequencies observed in each group and
Figure 1B summarizes the proportion of patients in each group exhibiting the other
eight cardinal features of OI.

Figure 3 – Genes implicated in genotyped patients.

Type I – Patients in this group had a wide range in the number of fractures they had

experienced from none (due to young age) to over 100 (due to multiple traumatic
incidents such as motor vehicle accidents), however the majority had had 20 fractures

or fewer. The presence of blue/grey sclera was the most prominent feature in this

group, particularly if the patient was genotyped. 84% of the genotyped patients had

blue/gray sclera while only 63% of the non-genotyped patients had blue/gray sclera, a

difference of 21%. However the difference was not statistically significant (Chi-Square
(1) = 1.76, p = 0.18). More than half of type I patients also had some degree of bone

density loss (osteoporosis or osteopenia) and ligament laxity. Roughly a quarter of this

group had DI, hearing loss and short stature. Bone deformity and scoliosis were only
present in a small percentage of this group. While there were only six out of 51 patients
with bone deformity, four or 21% of patients who were genotyped had bone deformity,
while only two patients or 6% of those from the non-genotyped group had bone

deformity. However, given the small sample of those with bone deformity, the

difference was not statistically significant (Fisher’s Exact test = 0.18). Scoliosis was
present in only six cases, but represented 16% of those in the non-genotyped group and
only 5% of those in the genotyped group.

The difference was not statistically

significant, given the small sample of those with scoliosis (Fisher’s Exact probability =
0.39).

Type IV – The sample size in this group was 25 patients. he fracture frequency in this

group was quite variable from a few to over 100 with no major pattern of distribution.

The other phenotypic features observed in most patients were short stature and

ligament laxity. Roughly half of the patients had blue/grey sclera, DI, and bone density
loss. Hearing loss, scoliosis and bone deformity were seen in roughly a third of the
patients in this group. Besides hearing loss which was observed at the same

approximate frequency in the genotyped, and not genotyped groups, features other
than fractures were observed less frequently in the genotyped group. In the Type IV
group 63% (15) had blue/gray sclera. This was 71% of those in the non-genotyped

group and only 45% of those in the genotyped group. The difference was not

statistically significant (Fisher’s Exact probability = 0.24). Likewise, 52% (13) had
dentinogenesis imperfecta. This represented 64% of those in the non-genotyped group

and only 36% of those in the genotyped group, a descriptive difference that was not
statistically significant (Fisher’s Exact probability = 0.24). In the Type IV group, 36%
(9) had bone deformity. 43% of those in the non-genotyped group and only 27% of

those in the genotyped group, a difference that was not statistically significant (Fisher’s
Exact probability = .68). In the type IV group, 68% (17) had ligament laxity. This was
79% of the non-genotyped group and only 55% of those in the genotyped group, a
difference that was not statistically significant (Fisher’s Exact probability = 0.39)

Genotype-Phenotype Relationship – Figure 3 illustrates the number and distribution
of patients who were genotyped. There were more individuals with type I than type IV

who had been genotyped. The majority of patients with type I OI had a mutation in
Col1α1 while the majority of type IV patients had a mutation in Col1α2. The three

patients with mutations in other genes are not currently typed within the classical
Sillence types. We constructed a genotype-phenotype map of the individuals who had a

mutation in either collagen type I gene (Figure 4). The mutations in our study subjects

were all private and only common amongst family members. As Figure 4 illustrates, we
observed nonsense, missense, frameshift and splice site mutations of Col1α1 at roughly

the same frequency. For Col1α2, missense mutations were predominant and there were

also frameshift mutations and one whole exon deletion. There appeared to be no

correlation between the type, identity or location of mutations with the resulting
phenotype.

DISCUSSION
Diagnostic Odyssey – One of the aims of this retrospective study was to examine

how genetic testing is utilized in the clinic to address the diagnostic dilemma of mild

and moderate forms of OI. Overall, we did not identify a set criteria that would be

clinically diagnostic of OI type I or IV. Fracture frequency, the hallmark feature of OI,

was highly variable in both patient groups ranging from few to over a hundred.

Additionally, individuals who were typed outside the classical Sillence types (based
on genotyping or a known mutation in the family), overlapped in terms of fracture

frequency with type I and IV groups. Secondary features associated with OI

including scleral hue, DI and hearing loss were also observed at variable rates and
did not contribute to a definitive diagnosis or typing. As expected the skeletal

phenotype was more involved in individuals with type IV with short stature and
ligament laxity being predominant. Our data supports the claim that diagnosing and

typing of mild and moderate types of OI strictly based on clinical features can be
subjective. We observed that genotyping appears to be utilized most often in the

most ambiguous cases. For example, a larger proportion of type I patients had been

genotyped had bone deformity (a feature usually absent in these mild cases),
compared to those not genotyped. In other words patients who had few fractures

and were therefore likely to be type I but had bone deformities atypical of type I,

presented as ambiguous cases that were resolved by genotyping. Likewise, in the

type IV population, individuals who had not been genotyped were more likely than
the genotyped individuals to exhibit all features except hearing loss. These are likely

to have appeared as ambiguous cases in that their fracture frequency implied type

IV, however, they appeared mildly or not at all affected with other features

commonly seen in type. The exception to this observation is that type I patients with

scoliosis were not genotyped at a higher rate, even though scoliosis is generally not

expected to be present in mild cases. This could indicate that presence or absence of

scoliosis does not provide strong clinical evidence in the diagnosis of OI. Of note,

while there were the mentioned descriptive differences between genotyped and

non-genotyped groups in the features, the differences were not statistically
significant due in part to the small sample size and the small number of patients
with the particular feature.

Genotype-Phenotype Correlations – Our analysis of the genotype-phenotype data
revealed that mutations in either Col1α1 or Col1α2 can lead to both type I and type

IV OI with no identifiable correlation with to mutation type, identity or location

along the genes. Still, the majority of type I cases were due to Col1α1 mutations and
almost all type IV cases were a result of Col1α2 mutations. In other words,

mutations in Col1α1 appear to result in milder phenotypes than Col1α2. This would
not be expected from a strictly stoichiometric standpoint given that each collagen

polymer is composed of two alpha 1 and one alpha 2 chains. The explanation for the
increased severity of a Col1α2 mutations compared to Col1α1, could instead be in

the functional consequences of the mutations. This is consistent with the idea that
type I OI is a result of quantitative defects caused by mutations in Col1α1 that result

in collagen haploinsufficiency and more severe OI types are a result of qualitative
defects due to mutations in Col1α2 that cause structural defects of collagen. These

hypotheses may be answered with further functional studies that examine the
protein products of these genes.

There were several findings that were not consistent with other studies of

genotype-phenotype correlations in OI, though we must keep in mind that the other
studies acknowledge possible exceptions to their generalizations. First, since

peptide translation occurs in the direction of C to N-terminus, it was expected that
the earlier the mutation occurred in the sequence, the more severe the outcome. We

did not observe any distinct pattern supporting this. In fact a notable exception was
a type IV patient who had experienced over 50 fractures who had a frameshift
mutation in the last exon (52) of Col1α1 (Figure 4). We hypothesize that either the

mutation causes a structural defect in the alpha 1 chain or the patient has modifier

genes that in combination with this mutation result in a more severe phenotype.

Second, we observed that individuals in the same family with the same genotype
had different phenotypes. This again could be due to modifier gene effects and in

turn makes predicting likely prognoses based on genotype less reliable. Third,
contrary to a general consensus that glycine substitutions result in structural

defects of either chain and therefore more severe phenotypes, we found that glycine

substitutions in the alpha 1 chain usually led to type I OI. Further functional analysis
is needed to elucidate the mechanisms underlying these observations.

Utility of Genetic Testing – In this study we illustrated that within our patient

cohort, it was not practical to identify a set of clinical criteria for the definitive

diagnosis or accurate typing of mild and moderate forms of OI. Traditionally,

biochemical analysis has served as the (confirmatory) diagnostic test for OI,

identifying culprits in about 90% of individuals with a clinical diagnosis (Wenstrup
et al., 1990). In contrast, genetic testing is both minimally invasive and can identify

the causative variants in more than 95% of affected individuals (Sykes et al.,

1990; Körkkö et al., 1998). In addition, in the prenatal setting, biochemical testing is
limited to chorionic villus samples and can only identify qualitative defects, with a
delay of 2-4 weeks for diagnosis in a time-sensitive context (Engel and Prockop,
1991).

When the primary purpose of investigation is to distinguish cases of child abuse and
OI (though they are not mutually exclusive), genetic testing is extremely valuable. It
is estimated that about 5% of suspected cases of child abuse are found to have OI

(Marlowe et al., 2002). With the high detection rate of genomic, the residual risk
that a child has OI after a negative genetic testing is less than 0.5%.

Given these considerations, we conclude that genetic analysis should be used as a

first tier testing modality in establishing and confirming a diagnosis of OI (in mild
and moderate types). Biochemical testing still has value in follow-up studies that

can shed light on to the pathogenicity of unclassified variants and functional

analysis of splice-site mutations. Though in our study we could not establish any

definitive genotype-phenotype correlations, as we collectively expand the variant

database, we may start to see reoccurrences of previously assumed “private”

mutations. In this way, having a genotype-phenotype map can help clinicians,
patients and families gain insight into the likely course of the condition and
therapeutic approaches.

Genotype information is particularly helpful in appropriate selection of available
therapies. Bisphosphonates and teriparatide are the two classes of medications

currently prescribed in the treatment of OI. The mechanism of action of both drugs

is to increase bone mass. Promoting an increase in bone mass is a wise approach in
OI types that are due to a quantitative defect of collagen. However in patients whose
gene alteration results in structurally defective collagen, promoting an increase in

defective collagen synthesis is counter-productive. Furthermore, those with
recessive types of OI that are phenotypically indistinguishable from classic types,

would not respond in the same way to these treatments because the therapeutic
target of these drugs do not align with the pathogenic pathways of recessive OI

types. Additionally, bisphosphnates appear to be less effective in adults (Chevrel et
al., 2006). Thus establishing an early and accurate diagnosis of OI plays an
important role in optimizing the clinical management of OI patients.

From a genetic counseling perspective, genotype information provides the most

accurate assessment of recurrence risks and is perhaps most useful in the setting of
prenatal and pre-implantation genetic diagnosis. This retrospective study reported

on the diagnostic experience of patients with mild and moderate forms of OI at the

Skeletal Dysplasias Clinic at the Hospital for Special Surgery and will serve as an

expandable tool to inform both clinicians and patient families about the practical
intricacies of the diagnosis and care of these patients.
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